Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation.

Kesanopoulos K, Bratcher HB, Hong E, Xirogianni A, Papandreou A, Taha MK, Maiden MCJ, Tzanakaki G.

PLoS One. 2018 Dec 28;13(12):e0209919. doi: 10.1371/journal.pone.0209919. eCollection 2018.

2.

Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland.

Mulhall RM, Bennett D, Cunney R, Borrow R, Lucidarme J, Findlow J, Jolley KA, Bray J, Maiden MCJ, Moschioni M, Serino L, Stella M, Medini D.

mSphere. 2018 Aug 22;3(4). pii: e00196-18. doi: 10.1128/mSphere.00196-18.

3.

Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.

Brehony C, Rodrigues CMC, Borrow R, Smith A, Cunney R, Moxon ER, Maiden MCJ.

Vaccine. 2016 Sep 7;34(39):4690-4697. doi: 10.1016/j.vaccine.2016.08.015. Epub 2016 Aug 9.

4.

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.

Medini D, Stella M, Wassil J.

Vaccine. 2015 May 28;33(23):2629-36. doi: 10.1016/j.vaccine.2015.04.015. Epub 2015 Apr 13. Review.

5.

Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.

Mowlaboccus S, Perkins TT, Smith H, Sloots T, Tozer S, Prempeh LJ, Tay CY, Peters F, Speers D, Keil AD, Kahler CM.

PLoS One. 2016 Jun 29;11(6):e0158315. doi: 10.1371/journal.pone.0158315. eCollection 2016.

6.

Meningococcal Carriage in Military Recruits and University Students during the Pre MenB Vaccination Era in Greece (2014-2015).

Tryfinopoulou K, Kesanopoulos K, Xirogianni A, Marmaras N, Papandreou A, Papaevangelou V, Tsolia M, Jasir A, Tzanakaki G.

PLoS One. 2016 Dec 1;11(12):e0167404. doi: 10.1371/journal.pone.0167404. eCollection 2016.

7.

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.

Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D.

Vaccine. 2013 Oct 9;31(43):4968-74. doi: 10.1016/j.vaccine.2013.08.006. Epub 2013 Aug 14.

8.

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.

Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R.

Lancet Infect Dis. 2013 May;13(5):416-25. doi: 10.1016/S1473-3099(13)70006-9. Epub 2013 Feb 13.

PMID:
23414709
9.

Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.

Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, Comanducci M, Muzzi A, Taha MK.

BMC Microbiol. 2014 Apr 29;14:111. doi: 10.1186/1471-2180-14-111.

10.

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK.

Vaccine. 2013 Feb 4;31(7):1113-6. doi: 10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20.

PMID:
23261039
11.

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT).

Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.

12.

Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010-2016.

Rodrigues CMC, Lucidarme J, Borrow R, Smith A, Cameron JC, Moxon ER, Maiden MCJ.

Emerg Infect Dis. 2018 Apr;24(4):673-682. doi: 10.3201/eid2404.171480.

13.

Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness.

Poolman JT, Richmond P.

Expert Rev Vaccines. 2015;14(9):1277-87. doi: 10.1586/14760584.2015.1071670. Epub 2015 Jul 23. Review.

PMID:
26204792
15.

Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine.

Green LR, Lucidarme J, Dave N, Chan H, Clark S, Borrow R, Bayliss CD.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00204-18. doi: 10.1128/JCM.00204-18. Print 2018 Sep.

16.

Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).

Gandhi A, Balmer P, York LJ.

Postgrad Med. 2016 Aug;128(6):548-56. doi: 10.1080/00325481.2016.1203238. Epub 2016 Jul 7. Review.

PMID:
27467048
17.

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.

Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R.

Lancet. 2014 Dec 13;384(9960):2123-31. doi: 10.1016/S0140-6736(14)60842-4. Epub 2014 Aug 18.

PMID:
25145775
18.

Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak-Oregon, 2015-2016.

McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, Martin S, Poissant T, Schmink SE, Steward-Clark E, Jenkins LT, Wang X, Acosta A; Oregon Meningococcal Carriage Team.

J Infect Dis. 2017 Nov 27;216(9):1130-1140. doi: 10.1093/infdis/jix446.

19.

Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.

Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeil JR, Martin SW, McNamara LA, Sicard K, Vanner C, Vuong J, Wang X, Bandy U, Patel M; Rhode Island Meningococcal Carriage Evaluation Team.

Clin Infect Dis. 2017 Apr 15;64(8):1115-1122. doi: 10.1093/cid/cix091.

20.

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.

Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani MM, Panatto D.

J Immunol Res. 2015;2015:353461. doi: 10.1155/2015/353461. Epub 2015 Aug 17. Review.

Supplemental Content

Support Center